Rivers E P, Wortsman J, Rady M Y, Blake H C, McGeorge F T, Buderer N M
Department of Emergency Medicine, Henry Ford Health Systems, Detroit.
Chest. 1994 Nov;106(5):1499-507. doi: 10.1378/chest.106.5.1499.
Studies evaluating the dose of epinephrine required to optimize return of spontaneous circulation and survival after CPR have shown that doses greater than recommended by advanced cardiac life support (ACLS) improve coronary perfusion pressure and short-term resuscitation rates. Since survival has not improved, it is possible that higher doses of epinephrine may be physiologically detrimental in the postresuscitation period.
The object of this study is to measure the effect of the total cumulative dose of epinephrine given during ACLS on the hemodynamic, oxygen transport, and utilization variables in the postresuscitation period.
A prospective nonrandomized control trial of inception cohorts.
A large urban emergency department and intensive care unit.
Forty-nine successfully resuscitated witnessed, normothermic, nontraumatic, out-of-hospital patients, who had suffered cardiac arrests.
All patients were treated according to ACLS guidelines; however, the epinephrine dose (0.01 to 0.2 mg/kg or 1 to 14 mg) was selected at the clinician's discretion and given through central venous access every 3 to 5 min. Hemodynamic, oxygen transport, and utilization variables were measured on a return of spontaneous circulation, and at least every 30 min thereafter under a standardized postresuscitation protocol.
Hemodynamic, oxygen transport/utilization variables, and mortality in patients resuscitated from cardiac arrest. The total cumulative dose of epinephrine given during ACLS until a return of spontaneous circulation was recorded.
A total cumulative epinephrine dose of 15 mg was found to best predict 24-h mortality. Of the 49 patients, 20 received less than 15 mg (group 1) and 29 received greater than 15 mg (group 2). Age, premorbid health status, sex, presenting rhythm, and duration of cardiac arrest were similar in both groups. The 24-h survival was 17 of 20 (85%) and 12 of 29 (41%) in group 1 and 2, respectively (p < 0.002). Over the first 6 h of the postresuscitation period, both groups had similar mean arterial pressure (MAP), mixed venous oxygen saturation, and systemic oxygen extraction ratio (all p > 0.1). Group 2, however, had a significantly lower cardiac index (CI), systemic oxygen consumption (VO2), and systemic oxygen delivery (DO2) (all p < 0.01). Systemic vascular resistance index (SVRI), initial and 6-h lactic acid levels were significantly higher in group 2 (all p < 0.03).
The administration of all doses of epinephrine during the resuscitation of out-of-hospital cardiac arrest is associated with impairment of DO2 and VO2 in the postresuscitation period. Both duration and severity of these impairments correlate with the total cumulative epinephrine dose given during the resuscitation. Thus, inadvertent catecholamine toxicity represents a further complicating factor in the production of postresuscitation disease. Diagnostic and therapeutic interventions addressed toward mitigating these potentially reversible adverse effects may impact morbidity and mortality in out-of-hospital cardiac arrests.
评估心肺复苏(CPR)后优化自主循环恢复及生存所需肾上腺素剂量的研究表明,高于高级心脏生命支持(ACLS)推荐剂量的肾上腺素可提高冠状动脉灌注压及短期复苏率。由于生存率并未提高,较高剂量的肾上腺素在复苏后期可能对生理有害。
本研究的目的是测量ACLS期间给予的肾上腺素总累积剂量对复苏后期血流动力学、氧输送及利用变量的影响。
一项起始队列的前瞻性非随机对照试验。
一家大型城市急诊科及重症监护病房。
49例成功复苏的目击、体温正常、非创伤性、院外心脏骤停患者。
所有患者均按照ACLS指南进行治疗;然而,肾上腺素剂量(0.01至0.2mg/kg或1至14mg)由临床医生酌情选择,并通过中心静脉通路每3至5分钟给予一次。在自主循环恢复时测量血流动力学、氧输送及利用变量,此后在标准化的复苏后方案下至少每30分钟测量一次。
心脏骤停复苏患者的血流动力学、氧输送/利用变量及死亡率。记录ACLS期间直至自主循环恢复时给予的肾上腺素总累积剂量。
发现肾上腺素总累积剂量为15mg最能预测24小时死亡率。49例患者中,20例接受的剂量小于15mg(第1组),29例接受的剂量大于15mg(第2组)。两组患者的年龄、病前健康状况、性别、初始心律及心脏骤停持续时间相似。第1组和第2组的24小时生存率分别为20例中的17例(85%)和29例中的12例(41%)(p<0.002)。在复苏后最初6小时内,两组患者的平均动脉压(MAP)、混合静脉血氧饱和度及全身氧摄取率相似(均p>0.1)。然而,第2组的心脏指数(CI)、全身氧消耗(VO2)及全身氧输送(DO2)显著较低(均p<0.01)。第2组的全身血管阻力指数(SVRI)、初始及6小时乳酸水平显著较高(均p<0.03)。
院外心脏骤停复苏期间给予的所有剂量肾上腺素均与复苏后期DO2和VO2受损有关。这些损害的持续时间和严重程度均与复苏期间给予的肾上腺素总累积剂量相关。因此,意外的儿茶酚胺毒性是复苏后疾病发生中的另一个复杂因素。旨在减轻这些潜在可逆性不良反应的诊断和治疗干预措施可能会影响院外心脏骤停的发病率和死亡率。